Harnessing the Power of the Immune System to Fight Cancer
At NewYork-Presbyterian Lawrence Hospital, we offer treatments that activate or turn on your immune system to fight cancer cells throughout your body — an approach called "immunotherapy." Over the past decade alone, the U.S. Food and Drug Administration (FDA) has approved several new immunotherapy drugs for advanced cancers such as metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma (kidney cancer). Many more are being evaluated in clinical trials. In addition to surgery, chemotherapy, radiation therapy, and interventional oncology, immunotherapy is considered the "fifth pillar" of cancer treatment.
NewYork-Presbyterian Columbia University Irving Medical Center investigators were involved in the evaluation of several of the immunotherapy drugs that have been approved by the FDA. At NewYork-Presbyterian Lawrence Hospital, we offer immunotherapies for many types of cancer, including melanoma, lung cancer, kidney cancer, breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, bladder cancer, and prostate cancer. You can receive these treatments in our modern and comfortable Infusion Center from an experienced and compassionate staff.
The National Cancer Institute-Designated Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center has a robust clinical research program featuring many clinical trials evaluating new immunotherapies and novel ways of combining immunotherapy with other cancer treatments. Our physicians at NewYork-Presbyterian/Lawrence are collaborating with these investigators and will refer our patients, if they are eligible, to participate in these pivotal clinical studies.